The clinical trials comparing Det regimes and Glar-100 in T2DM insulin-naïve subjects, or in subjects using the basal-bolus regime, failed to identify any significant differences in terms of the primary goal of achieving the specified HbA1c or FPG levels, or in the proportion of patients achieving the HbA1c goal without symptomatic hypoglycemia. This evidence concerns the gene INS and Hypoglycemia.